TNNI3 and coronary artery disorder: A recent analysis has shown that the use of hs-cTnI with threshold values of 2 ng/L and 6 ng/L enables the effective stratification of patients with stable ischemic heart disease into three risk categories for MACE: low-risk (<1% annual incidence), medium-risk (1–3% annually), and high-risk (>3% annually) cohorts.